New prostate cancer urine test shows how aggressive disease is and could reduce invasive biopsies

Published by  Communications

On 27th Apr 2021

Researchers from the University of East Anglia have developed a new urine test for prostate cancer which also shows how aggressive the disease is.

A new study published today shows how an experimental new test called ‘ExoGrail’ has the potential to revolutionise how patients with suspected prostate cancer are risk-assessed prior to an invasive biopsy.

The research team say their new test could reduce the number of unnecessary prostate cancer biopsies by 35 per cent.

Prostate cancer is the most common cancer in men in the UK. It usually develops slowly and the majority of cancers will not require treatment in a man’s lifetime.

The most commonly used tests for prostate cancer include blood tests, a physical examination known as a digital rectal examination (DRE), an MRI scan or an invasive biopsy.

However, doctors struggle to predict which tumours will become aggressive, making it hard to decide on treatment for many men.

Lead researcher Dr Dan Brewer, from UEA’s Norwich Medical School and also a visiting worker at the Earlham Institute, said: “While prostate cancer is responsible for a large proportion of all male cancer deaths, it is more commonly a disease men die with rather than from.

“Therefore, there is a desperate need for improvements in diagnosing and predicting outcomes for prostate cancer patients to minimise over-diagnosis and overtreatment whilst appropriately treating men with aggressive disease, especially if this can be done without taking an invasive biopsy.

“Invasive biopsies come at considerable economic, psychological and societal cost to patients and healthcare systems alike.”

The research team developed the new ExoGrail urine test by combining two biomarker sources - measurements of a protein-marker called EN2 and the levels of gene expression of 10 genes related to prostate cancer risk. It builds on previously developed tests called PUR and ExoMeth.

They tested it using urine samples from 207 patients who had been undergone a biopsy for prostate cancer at the Norfolk and Norwich University Hospital (NNUH).

When the urine results were compared to biopsy results, the study showed that the test had successfully shown which patients had prostate cancer and which did not.

The ExoGrail test also provided risk scores for patients and highlighted those for which an invasive biopsy would have been beneficial.

The findings show that using information from multiple, non-invasive biomarker sources has the potential to greatly improve how patients with suspected prostate cancer are risk-assessed prior to an invasive biopsy.

Dr Brewer said: “Our new urine test not only shows whether a patient has prostate cancer, but it importantly shows how aggressive the disease is. This allows patients and doctors to select the correct treatment. And it has the potential to reduce the number of unnecessary biopsies by 35 per cent.”

The research team was led by Dr Shea Connell, Prof Colin Cooper, Dr Daniel Brewer and Dr Jeremy Clark, all from UEA’s Norwich Medical School, in collaboration with the Norfolk and Norwich University Hospital, the University of Surrey, the University of Bradford, The Earlham Institute, and The Movember GAP1 Urine Biomarker Consortium. 

The urine biomarker research was funded by the Movember GAP1 Urine Biomarker project, Prostate Cancer UK, The Masonic Charitable Foundation, The Bob Champion Cancer Trust, the King family, The Andy Ripley Memorial Fund, the Hargrave Foundation, Norfolk Freemasons and the Tesco Centenary Grant.

Paul Villanti, executive director of programmes at Movember, said: “We are proud to have supported the development of the ExoGrail urine test as part of our Global Action Plan Urine Biomarker project.

“Having non-invasive tests which can accurately show how aggressive a man’s prostate cancer is not only reduces the number of men having to undergo painful biopsies, but also ensures that the right course of treatment for the patient is selected more quickly.”

Integration of Urinary EN2 Protein & Cell-Free RNA Data in the Development of a Multivariable Risk Model for the Detection of Prostate Cancer Prior to Biopsy’ is published in the journal Cancers on Tuesday, April 27, 2021.

Study with us

Explore our research

Latest News

 
A forest fire in the Amazon rainforest.
27 Jan 2023

Human activity has degraded more than a third of remaining Amazon rainforest

The Amazon rainforest has been degraded by a much greater extent than scientists previously believed, according to a new study.

Read more >
 
A child learning to write the alphabet.
27 Jan 2023

Poor literacy linked to worse mental health worldwide, study shows

Read more >
 
A Vitamin D tablet being held up to the sun.
26 Jan 2023

80-year-old medical mystery that caused baby deaths solved

Researchers at the University of East Anglia have solved an 80-year-old medical mystery that causes kidney damage in children and can be fatal in babies.

Read more >
 
A loudspeaker at a protest.
23 Jan 2023

There may be more power in the hand of the worker than previously thought

Employers who disproportionately punish striking workers may be acting unlawfully, according to new research from the University of East Anglia.

Read more >
Are you searching for something?
 
A loudspeaker at a protest.
23 Jan 2023

There may be more power in the hand of the worker than previously thought

Employers who disproportionately punish striking workers may be acting unlawfully, according to new research from the University of East Anglia.

Read more >
 
Two bottles of hormones held in a gloved hand.
14 Jan 2023

HRT could ward off Alzheimer’s among at-risk women

Hormone Replacement Therapy (HRT) could help prevent Alzheimer’s Dementia among women at risk of developing the disease – according to University of East Anglia...

Read more >
 
A thermometer against a blue sky with blazing sun
12 Jan 2023

2022 sixth warmest year on record for global temperature

Globally 2022 was the sixth warmest year in a series stretching back to 1850, according to figures released today by the Met Office and University of East Anglia.

Read more >
 
Photo of Heidi Crisp
01 Jan 2023

HSC apprentice shortlisted for finalist in prestigious awards

Occupational therapist apprentice, Heidi Crisp has been shortlisted as one of three finalist  for Apprentice of the Year in the Norfolk Apprenticeship Awards. 

Read more >
 
Andy Cammidge
24 Jan 2023

New research grant will investigate novel organic materials

Prof Andy Cammidge (CHE) and colleagues have been awarded £800k from the Engineering and Physical Sciences Research Council to investigate the synthesis of new...

Read more >
 
James Bevan presenting at UEA. He is wearing glasses, a black jacket and grey trousers.
24 Jan 2023

UEA praised for 'outstanding' work on climate research

Sir James Bevan, Chief Executive of the Environment Agency, praised UEA’s outstanding work on climate research and highlighted the need to focus on climate...

Read more >
 
Steve Smith holding his award up with another person. Steve is wearing a grey suit.
11 Jan 2023

Nur-sing when you’re winning

National nursing award announced for retired university academic Steve Smith, aka the ‘Singing Lecturer’.

Read more >